1379545-29-5

Basic information

• Product Name: [3-({[4-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-yl]oxy}methyl)phenyl]boronic acid
• Synonyms: [3-({[4-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-yl]oxy}methyl)phenyl]boronic acid
• CAS NO: 1379545-29-5
• Molecular Weight: 418.098
• Mol File: 1379545-29-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [3-({[4-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-yl]oxy}methyl)phenyl]boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [3-({[4-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-yl]oxy}methyl)phenyl]boronic acid(1379545-29-5)
• EPA Substance Registry System: [3-({[4-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-yl]oxy}methyl)phenyl]boronic acid(1379545-29-5)

Safety Data

• Hazardous Substances Data: 1379545-29-5(Hazardous Substances Data)

Upstream product

• 1268314-66-4 N₁-(2,2-dimethylpropyl)-4-methoxybenzene-1,2-diamine 
• 1268314-65-3 N-(2,2-dimethylpropyl)-4-methoxy-2-nitroaniline 
• 1268314-64-2 4-bromo-1-(2,2-dimethylpropyl)-5-methoxy-1H-1,2,3-benzotriazole 
• 1247947-90-5 1-(2,2-dimethylpropyl)-5-nitro-1H-1,2,3-benzotriazole 
• 1247947-91-6 1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-amine 
• 908288-73-3 1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-ol 
• 908288-77-7 4-bromo-1-(2,2-dimethylpropyl)-1H-1,2,3-benzotriazol-5-ol 
• 51323-43-4 (3-(bromomethyl)phenyl)boronic acid 
• 630-19-3 pivalaldehyde 
• 5813-64-9 2.2-dimethylpropylamine 
• 96-96-8 4-methoxy-2-nitroaniline 
• 369-36-8 6-fluoro-3-nitroaniline 

Downstream Products

• 1379541-44-2 3'-({[4-bromo-1-(2,2-dimethylpropyl)-1H-benzotriazol-5-yl]oxy}methyl)-5-fluorobiphenyl-3-carboxylic acid 

Relevant articles and documents

ETHER BENZOTRIAZOLE DERIVATIVES

The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.